04 June 2024
04 June 2024
Precede Bio’s liquid biopsy assay could help to guide treatment options for patients with HER2 or ER+ cancers.
We are thrilled to introduce our latest development: ultrasound beamformer ArtUs COEM-1H. This OEM component provides the functionality and features of our full-size ArtUs scanners in a significantly more compact volume.
The partnership aims to expand access to Mika’s digital oncology platform, with the app being distributed among Massive Bio’s patient base.
The pivotal trial will include patients with functional mitral regurgitation at high surgical risk.
A new saliva test could identify men at higher risk of prostate cancer earlier and result in better treatment outcomes.
The sale will allow Edwards Lifesciences to focus on structural heart disease technologies.
Artelon is engaged in providing soft tissue fixation products for foot, ankle and sports medicine procedures.
This authorisation enables OTC and POC use, offering a rapid, simultaneous detection of Covid-19, as well as influenzas A and B.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
